Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey-Reference-Cited by-同舟云学术

Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey

Published:2015-10-07 Issue:4 Volume:2 Page:335-344
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Ishihara Lianna,Beck Melissa,Travis Sara,Akintayo Olusegun,Brickel Neil

Funder

GlaxoSmithKline

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40801-015-0042-5.pdf

Reference15 articles.

1. GlaxoSmithKline. POTIGA (retigabine) package insert. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022345s006lbl.pdf . Accessed 23 Mar 2015.

2. Brickel N, Gandhi P, VanLandingham KE, Hammond J, DeRossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia. 2012;53(4):606–12.

3. Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817–24.

4. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68(15):1197–204.

5. Porter RJ, Burdette DE, Gil-Nagel A, Hall ST, White R, Shaikh S, et al. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res. 2012;101(1–2):103–12.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024;Expert Opinion on Drug Safety;2024-09-13

2. Evolution of Cross-Sectional Survey Protocol Quality Over Time: A Case Series of Index U.S. REMS Knowledge Survey Protocols (2007–2020);Drug Safety;2023-09-12

3. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries;Expert Opinion on Drug Safety;2021-11-22

4. A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs;Drug Safety;2021-04-27

5. Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019;JAMA;2020-07-21